Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04422314 · ClinicalTrials.gov registry record
ImmuneSense Lyme Study
A clinical trial of Lyme Disease, sponsored by Adaptive Biotechnologies.
- Completed
- Registry status
- 893
- Enrollment target
- 20
- Study locations
NCT04422314 is a study of Lyme Disease that has completed, run by Adaptive Biotechnologies. The registered enrollment target is 893 participants, below the 3,775-participant average among 9 other Lyme Disease trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT04422314, a study of Lyme Disease, has completed, sponsored by Adaptive Biotechnologies.
- COMPLETED
- Registry status
- 893 participants
- Enrollment target
- 20
- Study locations
Study Summary
ImmuneSense Lyme is a study, which is designed to better understand the immune response to Lyme disease. This is critically important because the immune system may be able to tell us important information about how our own bodies detect and respond to the disease that current tests cannot. Data collected from this study may accelerate the development of better diagnostics for Lyme disease and improve outcomes for many.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST T-Detect Lyme
Study Locations (20)
New York
- Adaptive Biotechnologies Investigational Site - Binghamton
- Adaptive Biotechnologies Investigational Site - Endwell
- Adaptive Biotechnologies Investigational Site - New Windsor
- Adaptive Biotechnologies Investigational Site - Syracuse
Pennsylvania
- Adaptive Biotechnologies Investigational Site - Altoona
- Adaptive Biotechnologies Investigational Site - Altoona
- Adaptive Biotechnologies Investigational Site - Hatboro
- Adaptive Biotechnologies Investigational Site - Pittsburgh
Maryland
- Adaptive Biotechnologies Investigational Site - Elkridge
- Adaptive Biotechnologies Investigational Site - Rockville
- Adaptive Biotechnologies Investigational Site - Towson
Massachusetts
- Adaptive Biotechnologies Investigational Site - Beverly
- Adaptive Biotechnologies Investigational Site - Methuen
- Adaptive Biotechnologies Investigational Site - Springfield
Georgia
- Adaptive Biotechnologies Investigational Site - Macon
- Adaptive Biotechnologies Investigational Site - Savannah
Connecticut
- Adaptive Biotechnologies Investigational Site - Danbury
Louisiana
- Adaptive Biotechnologies Investigational Site - Baton Rouge
Maine
- Adaptive Biotechnologies Investigational Site - Lewiston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 893 participants |
| Start Date | 2020-07-09 |
| Est. Completion | 2021-10-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04422314
The ClinicalTrials.gov registry entry for NCT04422314 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 893 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,775-participant average among 9 other Lyme Disease trials with a reported enrollment target (76% lower). The listed sponsor is Adaptive Biotechnologies, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lyme Disease appearing as the primary indexed condition, and to 1 intervention - of which T-Detect Lyme is the first listed.
NCT04422314 reports 20 study locations spanning 9 distinct geographic areas - top geographies include New York, Pennsylvania, Maryland.
Frequently Asked Questions
What is clinical trial NCT04422314 about?
NCT04422314 is a clinical study titled "ImmuneSense Lyme Study". ImmuneSense Lyme is a study, which is designed to better understand the immune response to Lyme disease. This is critically important because the immune system may be able to tell us important information about how our own bodies detect and respond to the disease that current tests cannot. Data coll...
What is the current status of trial NCT04422314?
This trial is currently completed. The enrollment target is 893 participants. The study started on 2020-07-09. Estimated completion is 2021-10-30.
What conditions does trial NCT04422314 study?
This clinical trial studies the following conditions: Lyme Disease.
What interventions are being tested in trial NCT04422314?
The interventions under investigation include: T-Detect Lyme (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04422314?
This trial is sponsored by Adaptive Biotechnologies, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04422314 being conducted?
This trial has 20 study locations across Connecticut, Georgia, Louisiana, Maine, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lyme Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Human Immune Response to Ixodes Scapularis Tick Bites
RECRUITING · Phase 1
-
Pregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure
RECRUITING
-
A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations
RECRUITING
-
Navigating Pregnancy and Parenthood With Lyme Disease
RECRUITING
-
Evaluation, Treatment, and Follow-up of Patients With Lyme Disease
RECRUITING
-
An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.